Holen Sie sich die Stockscreener-App
15.48
1.24%
0.19
Handel nachbörslich:
15.55
0.07
+0.45%
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Zacks Investment Research
Ultragenyx sells PRV for $210M and still has another voucher it plans to monetize - Endpoints News
Ultragenyx shares rise 3.2% after selling FDA p... - Pluang
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Jumps 3.9%Here's Why - MarketBeat
Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity - TradingView
Ultragenyx (RARE) Stock Rises on $210M Priority Review Voucher S - GuruFocus
Ultragenyx to sell FDA priority review voucher for $210M (RARE) - Seeking Alpha
Ultragenyx to sell rare disease priority review voucher for $210m - Investing.com
Ultragenyx (RARE) Sells Rare Pediatric Disease Priority Review V - GuruFocus
Ultragenyx PharmaceuticalUnder Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih - TradingView
Ultragenyx to Sell Priority Review Voucher for $210 Million; 20% Payable to NIH - TradingView
A voucher that can speed FDA review is set to sell for $210 million. - Stock Titan
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million - GlobeNewswire
Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million - Proactive financial news
Ultragenyx (RARE) EMA Validation of MPS IIIA Gene Therapy: Inflection Point or Incremental Milestone? - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OSI Systems, Inc.OSIS - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - GlobeNewswire Inc.
Ultragenyx Pharmaceutical Inc. (RARE) stock price, news, quote and history - Yahoo Finance UK
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 6%Here's Why - MarketBeat
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation - Yahoo Finance
Ultragenyx Pharmaceutical Inc. (RARE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ultragenyx says EMA validates MPS IIIA application - Mugglehead Investment Magazine
Ultragenyx Announces Marketing Authorisation Application - GlobeNewswire
Ultragenyx Pharmaceutical Inc. (RARE.MX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Ultragenyx Pharmaceutical Inc. (RARE) Options Chain - Yahoo! Finance Canada
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Operating margin % of Ultragenyx Pharmaceutical, Inc. – HAN:UP0 - TradingView
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Up 5.8%Time to Buy? - MarketBeat
Cash flow from operating activities of Ultragenyx Pharmaceutical, Inc. – HAN:UP0 - TradingView
Return on invested capital % of Ultragenyx Pharmaceutical, Inc. – HAN:UP0 - TradingView
Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat - BioSpace
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analysts - MarketBeat
H.C. Wainwright reiterates Ultragenyx stock rating on FDA approval - Investing.com
H.C. Wainwright reiterates Ultragenyx stock rating on FDA approval - Investing.com India
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire
A Hedge Fund Rolls the Dice on Ultragenyx - Law Street Media
A Hedge Fund Rolls the Dice on Ultragenyx - Law Street Media
Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty - Stocktwits
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz - BioSpace
Treatment invented at Nationwide Children’s for kid-killing disease gets FDA approval - The Business Journals
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target? - Yahoo Finance
Bank of America Corp DE Invests $38.35 Million in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat
Why Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Is In Focus Now? - Kalkine Media
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):